Caris Life Sciences, Inc. (CAI) — SEC Filings
Caris Life Sciences, Inc. (CAI) — 9 SEC filings. Latest: 10-Q (May 8, 2026). Includes 4 8-K, 2 10-Q, 2 S-1/A.
View Caris Life Sciences, Inc. on SEC EDGAR
Overview
Caris Life Sciences, Inc. (CAI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: Caris Life Sciences, Inc. reported a significant increase in total revenue for the nine months ended September 30, 2025, reaching $519.1 million, up from $282.3 million in the same period of 2024, representing an 83.9% increase. This growth was primarily driven by molecular profiling services, which
Sentiment Summary
Across 9 filings, the sentiment breakdown is: 1 bullish, 7 neutral, 1 mixed. The dominant filing sentiment for Caris Life Sciences, Inc. is neutral.
Filing Type Overview
Caris Life Sciences, Inc. (CAI) has filed 2 10-Q, 4 8-K, 2 S-1/A, 1 S-1 with the SEC between May 2025 to May 2026.
Filings by Year
Recent SEC Filings (9)
| Date | Form | Description | Risk |
|---|---|---|---|
| May 8, 2026 | 10-Q | 10-Q Filing | |
| May 7, 2026 | 8-K | 8-K Filing | |
| Nov 5, 2025 | 10-Q | Caris Life Sciences Revenue Soars 84% Amid IPO Capital Infusion | medium |
| Oct 30, 2025 | 8-K | Caris Life Sciences Files 8-K for Corporate Changes | low |
| Aug 12, 2025 | 8-K | Caris Life Sciences Files 8-K on Financials | low |
| Jun 20, 2025 | 8-K | Caris Life Sciences Files 8-K | low |
| Jun 16, 2025 | S-1/A | Caris Life Sciences Amends S-1 for Public Offering | medium |
| Jun 9, 2025 | S-1/A | Caris Life Sciences Files S-1/A for IPO, Eyes Public Market Debut | medium |
| May 23, 2025 | S-1 | Caris Life Sciences Files S-1 for Public Debut, Eyes Growth in Precision Medicine | medium |
Risk Profile
Risk Assessment: Of CAI's 7 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $519.1M |
| Net Income | -$150.0M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $754.7M |
| Operating Margin | N/A |
| Total Assets | $984.6M |
| Total Debt | $506.2M |
Key Executives
- David D. Halbert
- Nathan Ajiashvili
- Alison Haggerty
- Samer Zabaneh
- Eric Blanchard
- Divakar Gupta
- Charles S. Kim
- J. Russel Denton
- Ginger Appleberry
- Michael R. Sullivan
Industry Context
The molecular diagnostics and precision medicine market is experiencing rapid growth, driven by advancements in genomic sequencing and the increasing demand for personalized cancer treatments. Companies in this space focus on developing and commercializing diagnostic tests that can identify specific biomarkers to guide therapy selection. The competitive landscape includes established diagnostic companies, emerging biotech firms, and academic research institutions, all vying for market share and technological leadership.
Top Tags
IPO (4) · Precision Medicine (3) · Biotechnology (3) · Medical Diagnostics (2) · SEC Filing (2) · Precision Oncology (1) · Biopharma (1) · Molecular Profiling (1) · Revenue Growth (1) · Net Loss (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $519.1M | Increased by 83.9% for the nine months ended September 30, 2025, from $282.3M in 2024 |
| Molecular Profiling Services Revenue | $484.6M | Increased by 90.3% for the nine months ended September 30, 2025, from $254.7M in 2024 |
| Net Loss | $150.0M | For the nine months ended September 30, 2025, an improvement from $244.9M loss in 2024 |
| Cash, Cash Equivalents, and Restricted Cash | $754.7M | As of September 30, 2025, up from $65.4M at December 31, 2024 |
| Proceeds from Initial Public Offering | $528.5M | Net of underwriting discounts and commissions for the nine months ended September 30, 2025 |
| Total Liabilities | $506.2M | Decreased from $620.9M at December 31, 2024, to September 30, 2025 |
| Research and Development Expense | $69.7M | Decreased from $86.8M for the nine months ended September 30, 2024 |
| Selling and Marketing Expense | $123.4M | Increased from $115.1M for the nine months ended September 30, 2024 |
| Changes in Fair Value of Financial Instruments | $52.3M | Loss for the nine months ended September 30, 2025, compared to a $6.1M gain in 2024 |
| Common Stock Shares Outstanding | 282,146,923 | As of November 3, 2025 |
| SEC File Number | 001-42706 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 85-2077369 | Company's tax identification number. |
| IRS Employer Identification Number | 85-2077369 | Unique identifier for tax purposes. |
| Central Index Key (CIK) | 0002019410 | Unique identifier for Caris Life Sciences, Inc. with the SEC. |
| Standard Industrial Classification (SIC) Code | 8071 | Indicates Caris Life Sciences operates in Medical Laboratories. |
Frequently Asked Questions
What are the latest SEC filings for Caris Life Sciences, Inc. (CAI)?
Caris Life Sciences, Inc. has 9 recent SEC filings from May 2025 to May 2026, including 4 8-K, 2 10-Q, 2 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CAI filings?
Across 9 filings, the sentiment breakdown is: 1 bullish, 7 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Caris Life Sciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Caris Life Sciences, Inc. (CAI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Caris Life Sciences, Inc.?
Key financial highlights from Caris Life Sciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CAI?
The investment thesis for CAI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Caris Life Sciences, Inc.?
Key executives identified across Caris Life Sciences, Inc.'s filings include David D. Halbert, Nathan Ajiashvili, Alison Haggerty, Samer Zabaneh, Eric Blanchard and 5 others.
What are the main risk factors for Caris Life Sciences, Inc. stock?
Of CAI's 7 assessed filings, 0 were flagged high-risk, 4 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Caris Life Sciences, Inc.?
Forward guidance and predictions for Caris Life Sciences, Inc. are extracted from SEC filings as they are enriched.